Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111)
. No severe vaso-occlusive events (VOEs) were reported through 24 months of follow up in Group C patients of the HGB-206…
. No severe vaso-occlusive events (VOEs) were reported through 24 months of follow up in Group C patients of the HGB-206…
Global Erythropoietin Drug Market - Scenario: Erythropoietin drugs are also known as hematopoietin. It is a glycoprot…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company, announced the treatment start o…
Patient recruitment for clinical Phase I in Phase I/II DC vaccine study successfully completed All patients treated with…
When we think of how we fight disease, the image of cells in our immune system fending off microbial invaders often come…
The AIT Austrian Institute of Technology has been awarded a contract to develop "Good Practices in the Field of Blood Tr…
Galenica increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013. On a comparable basis, profit before d…
The Galenica Group increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013, in a market environment char…
The Galenica Group performed well in a complex market environment during the first six months of 2013. Net sales increas…
Injectafer® has received US Food and Drug Administration (FDA) approval for the treatment of Iron Deficiency Anaemia (ID…